IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.6111
-0.0049 (-0.80%)
At close: Jan 30, 2026, 4:00 PM EST
0.6014
-0.0097 (-1.59%)
After-hours: Jan 30, 2026, 7:35 PM EST
IceCure Medical Employees
As of December 31, 2024, IceCure Medical had 66 total employees, including 64 full-time and 2 part-time employees. The number of employees decreased by 11 or -14.29% compared to the previous year.
Employees
66
Change (1Y)
-11
Growth (1Y)
-14.29%
Revenue / Employee
$45,076
Profits / Employee
-$231,667
Market Cap
42.14M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 66 | -11 | -14.29% | 64 | 2 |
| Dec 31, 2023 | 77 | 5 | 6.94% | 71 | 6 |
| Dec 31, 2022 | 72 | 8 | 12.50% | 65 | 7 |
| Dec 31, 2021 | 64 | 17 | 36.17% | 55 | 9 |
| Dec 31, 2020 | 47 | - | - | 40 | 7 |
Related Stocks
| Company Name | Employees |
|---|---|
| TELA Bio | 209 |
| Myomo | 185 |
| Cytosorbents | 149 |
| Baird Medical Investment Holdings | 143 |
| Spectral AI | 78 |
| VolitionRx | 75 |
| electroCore | 73 |
| Pulsenmore | 58 |
ICCM News
- 4 days ago - IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer - PRNewsWire
- 20 days ago - IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales - PRNewsWire
- 6 weeks ago - IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer - PRNewsWire
- 7 weeks ago - IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting - PRNewsWire
- 2 months ago - IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes - PRNewsWire
- 2 months ago - IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 - PRNewsWire
- 2 months ago - IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer - PRNewsWire